Major Update: Remdesivir for Adults With COVID-19
Open Access
- 1 May 2021
- journal article
- review article
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 174 (5) , 663-672
Abstract
Remdesivir is being studied for the treatment of COVID-19. This first update of a living rapid review used to inform American College of Physicians Practice Points includes information from a newly... Background: Remdesivir is being studied and used for treatment of coronavirus disease 2019 (COVID-19). Purpose: To update a previous review of remdesivir for adults with COVID-19, including new met...Keywords
This publication has 12 references indexed in Scilit:
- Covid-19: What now for remdesivir?BMJ, 2020
- Remdesivir for 5 or 10 Days in Patients with Severe Covid-19New England Journal of Medicine, 2020
- Remdesivir for the Treatment of Covid-19 — Final ReportNew England Journal of Medicine, 2020
- Efficacy of Remdesivir in COVID-19JAMA, 2020
- Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19JAMA, 2020
- A living WHO guideline on drugs for covid-19 (2020-2023)BMJ, 2020
- Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trialThe Lancet, 2020
- Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoVNature Communications, 2020
- A Randomized, Controlled Trial of Ebola Virus Disease TherapeuticsNew England Journal of Medicine, 2019
- Measuring inconsistency in meta-analysesBMJ, 2003